The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in patients with advanced solid tumors.
 
Nobuaki Matsubara
Consulting or Advisory Role - AstraZeneca; Janssen
Speakers' Bureau - AstraZeneca; Chugai Pharma; Janssen; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Bayer; Janssen; Shionogi
 
Kohei Shitara
Honoraria - Chugai Pharma; Takeda
Consulting or Advisory Role - Bayer; Chugai Pharma; Lilly
Research Funding - Bayer; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Sanofi; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Yoichi Naito
No Relationships to Disclose
 
Yasutoshi Kuboki
No Relationships to Disclose
 
Izumi Ohno
No Relationships to Disclose
 
Hideaki Takahashi
Honoraria - Novartis
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bayer
 
Hideaki Bando
Research Funding - AstraZeneca
 
Takashi Kojima
Research Funding - Ono Pharmaceutical
 
Nozomu Fuse
No Relationships to Disclose
 
Tomoko Yamazaki
No Relationships to Disclose
 
Naoki Hirayama
Employment - Taiho Pharmaceutical
Stock and Other Ownership Interests - Otsuka
 
Hidenori Fujita
Employment - Taiho Pharmaceutical
Stock and Other Ownership Interests - Otsuka
 
Toshirou Nishida
Honoraria - Bayer; Novartis; Pfizer
Research Funding - Bayer; Novartis
 
Toshihiko Doi
Honoraria - Chugai Pharma; Novartis
Consulting or Advisory Role - Amgen; Lilly Japan; Merck Serono; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); NanoCarrier (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)